NN&I “Magnetic Technology for creating AV Fistulas”

Study shows arteriovenous fistula can be created with magnetic technology instead of open surgery

A new, minimally invasive system which uses radiofrequency energy instead of open surgery to create arteriovenous fistulas for patients needing hemodialysis, is reliable, with minimal complications, according to data published in the American Journal of Kidney Disease.

Dr. Charmaine Lok, principal investigator of the trial

A one year, single arm, prospective study of 80 pre-dialysis and dialysis patients from nine centers in Canada, Australia, and New Zealand showed that an AV fistula was created successfully in 98 percent of all cases, with 87 percent being physiologically suitable for dialysis within three months of creation by this new magnet-based endovascular technology. Sixty-four percent of the AV fistulas were functionally used for dialysis within 12 months.

Thrombosis or clots formed in 1.8 percent of AV-fistulas within three months and 10.5 percent within 12 months – lower than that reported in current AV-fistulas created by open surgery. Studies have reported that from 14 to 26 per cent of traditional fistulas had clots within 12 months, according to background infomartion reported in the study.

“Chronic kidney patients currently do not have a minimally invasive option for creating AV-fistulas and yet it could reduce a significant barrier for patients to have an AV-fistula, which is the preferred access for hemodialysis. Patients often refuse AV-fistula creation because they do not want to undergo open surgery, and this technology can provide another option for patients,” said Charmaine Lok, MD, Medical Director of the Chronic Kidney Diseases and Hemodialysis Programs at the Toronto General Hospital, University Health Network principal investigator of the trial.

About the procedure

Using the everlinQ endoAVF System by TVA Medical, one magnetic catheter was inserted into the ulnar artery via the brachial artery, and one magnetic catheter was inserted into the ulnar vein via the brachial vein. The vessels were drawn together by the magnets. A small burst of radiofrequency energy, given through the catheters, was then used to create a connection between the artery and vein, creating the AV-fistula. The catheters were then removed leaving no surgical scar. These study procedures were performed on outpatients who did not need general anesthesia.

The everlinQ endoAVF System is under review with the U.S. Food and Drug Administration and is approved for use in Canada and Europe.

The study, entitled, “Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the prospective, multicenter Novel Endovascular Access Trial (NEAT),” is published online in the American Journal of Kidney Disease.

“This novel technology is a substantial benefit to our hemodialysis patients,” said Dheeraj Rajan, MD, the co-primary investigator in the study and Vascular/Interventional Radiologist at University Health Network’s Joint Department of Medical Imaging.“We can now access veins and arteries that otherwise would not be easily accessible via surgery, and we can do this in a safe, quick way that is easy for our patents to tolerate.”

Home Dialyzors United

Our Day, Our Way

Sign up and receive our latest updates!

With this information HDU can keep you informed of news and issues, including one quarterly Newsletter.

You may, of course, choose to opt out at any time by contacting HDU at HDUinfo@homedialyzorsunited.org.

Click Here to go directly to the website.

It has been Nichole Jefferson‘s personal mission to tell her story and promote awareness. She was diagnosed with end-stage renal disease (ESRD) in October 2003. At that time, not only was she unaware of what that meant; she also did not know she was a high-risk factor for developing the disease.
After the initial shock of the diagnosis, she decided peritoneal dialysis (PD) was the best option and utilized PD for a few years until she needed to switch to hemodialysis.
She received a kidney transplant from a deceased donor on June 12, 2008, but at the time, she didn’t realize it was simply another form of treatment and not a cure. Today, Nichole is waiting for a new transplant.
Nichole has worked with many advocacy groups on Capitol Hill and has provided her personal experience with ESRD to leaders in the field of nephrology. She tries to express the feelings of those who are unable or unwilling to speak for themselves.